ALC Stock Recent News
ALC LATEST HEADLINES
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.
ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation.
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.
GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.
Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The Retinal Surgery Devices Market is expected to reach US$ 4.84 billion in 2033 from US$ 2.48 billion in 2024, with a CAGR of 7.71% from 2025 to 2033. Some of the main reasons propelling the market include the rising prevalence of a number of eye ailments, increased awareness of eye issues and available treatments, and the expanding use of minimally invasive (MI) surgical technology. Rising prevalence of retinal diseases The market for retinal surgery instruments is mostly driven by the increasing incidence of retinal disorders. Age-related macular degeneration (AMD), diabetic retinopathy, and retinal detachment are among the conditions that are growing increasingly prevalent, especially as the world's population ages and the prevalence of diabetes rises. The need for sophisticated ret
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (“Algoma”, “Company”) (TSX: ALC) has achieved a significant milestone, taking delivery of three new ships, from three different countries, within one week for the first time in Company history. Since 2013, Algoma has built 23 vessels with 12 more on order or under construction. “This milestone reflects Algoma's commitment to making significant capital investments to meet our customers' needs - in the U.S., Canada, and internat.